| Ytd | -75.45% | |
| 1y | -86.99% |
| Open | 0.47 | Prev Close | 0.45 | Low | 0.46 | High | 0.53 | Mkt Cap | 6.92M |
| Vol | 436.33K | Avg Vol | 1.73M | EPS | -2.14 | P/E | N/A | Forward P/E | -9.31 |
| Beta | 7.68 | Short Ratio | 0.66 | Inst. Own | 13.72% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.66 | 200-d Avg | 1.73 | 1yr Est | 6.30 |
VVOS News
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical
LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Compan
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical
Key Terms of the Proposed Rights OfferingExercise price: Each right is expected to entitle the holde
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical
Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading me
Top Wall Street analysts updated ratings on CRWD, OLLI, XPO, SHAK, UNH, PVH, VVOS, and SYRE. See ana
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and r